CA9 and neoplasm: Indeed, PET/CT-based tumor visualization with 89Zr-labeled anti-CAIX antibodies ([89Zr]Zr-girentuximab) can aid diagnosis of localized and metastatic ccRCC and enable differentiation of indolent versus benign tumors, which is challenging with conventional imaging (10–12).